Home Cancer Genetics and Molecular Tumor Testing Hereditary Cancer Genetic Panel Test: Cancer Risk Genes and Results

Hereditary Cancer Genetic Panel Test: Cancer Risk Genes and Results

By
Vita Library
-
34
Learn how hereditary cancer genetic panels test multiple risk genes, who should be tested, what positive, negative, and VUS results mean, and how findings guide care.

A hereditary cancer genetic panel examines multiple genes for inherited variants that raise the risk of certain cancers. It is performed on blood, saliva, or another non-tumor sample and can identify syndromes involving breast, ovarian, prostate, pancreatic, colorectal, endometrial, kidney, endocrine, skin, and other cancers. The appropriate panel is not necessarily the largest one available. It should include genes supported by the person’s cancer type, age, pathology, ancestry, and family history, while avoiding genes whose results would be difficult to use. A pathogenic or likely pathogenic variant may change treatment, screening, risk-reducing surgery, and relatives’ care. A negative result can be reassuring when a known family variant is absent, but it may be uninformative when no cause has been established. A variant of uncertain significance should not direct surgery or predictive testing. Genetic counseling helps translate a long laboratory report into a plan based on the strength of evidence for each gene.

  • A hereditary cancer panel tests germline DNA, so it evaluates inherited risk rather than only mutations acquired within a tumor.
  • A pathogenic or likely pathogenic result can affect both treatment and prevention, but recommendations differ by gene, cancer type, sex, and age.
  • A negative result is most definitive when the family’s exact pathogenic variant is known and the tested person did not inherit it.
  • A variant of uncertain significance is not a positive diagnosis and should not be used alone for preventive surgery or family predictive testing.
  • Relatives of a person with a pathogenic variant usually need targeted testing for that variant, not a new broad panel as the first step.

Table of Contents

What a hereditary cancer panel tests

A hereditary cancer panel looks for germline variants: DNA changes present from conception in most or all cells. The test usually analyzes dozens of genes at once, although focused panels may contain fewer than ten and broad panels may contain more than one hundred.

Most cancer-predisposition genes act as tumor suppressors, DNA-repair genes, or growth-signaling regulators. A person may inherit one nonworking copy and later develop a tumor after the remaining copy is lost or another pathway is disrupted. Other genes cause risk through different mechanisms.

Common panel groups include:

  • Breast, ovarian, pancreatic, and prostate genes, such as BRCA1, BRCA2, PALB2, ATM, CHEK2, TP53, PTEN, CDH1, STK11, and others.
  • Colorectal and endometrial genes, including MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MUTYH, SMAD4, BMPR1A, STK11, POLE, POLD1, and additional polyposis genes.
  • Hereditary kidney cancer genes, such as VHL, FLCN, FH, MET, BAP1, SDHB, TSC1, and TSC2.
  • Endocrine tumor genes, including RET, MEN1, CDC73, VHL, SDHx genes, MAX, TMEM127, and others.
  • Melanoma and nervous-system tumor genes, such as CDKN2A, BAP1, NF1, NF2, and selected DNA-repair genes.

A panel may include high-penetrance genes, in which pathogenic variants can create a large lifetime risk, and moderate-penetrance genes, whose risks are smaller or more dependent on family history. Some genes have clear management guidelines; others have limited data. A larger panel therefore increases both diagnostic opportunity and interpretive complexity.

The test usually searches for single-letter changes, small insertions or deletions, and larger exon or whole-gene deletions and duplications. Some panels assess promoter variants, deep intronic changes, repetitive regions, pseudogene-related sequences, or mosaic variants, while others do not. The methods section should be reviewed for technically difficult genes such as PMS2.

A hereditary panel is different from tumor sequencing. Tumor testing examines acquired changes that may guide therapy. It can suggest a possible inherited variant, but it may miss germline changes or detect tumor-only alterations. Patients who meet criteria for germline testing should generally receive a dedicated germline genetic test regardless of a negative tumor result.

A panel is also different from consumer ancestry or wellness testing. Clinical laboratories confirm identity, use validated methods, classify variants under professional standards, and issue a report intended for medical care.

Who should consider panel testing

Testing indications have broadened because inherited results can guide targeted treatment and because age or family-history rules miss some carriers. Recommendations differ by cancer type and are updated regularly.

Common reasons for testing include:

  • breast cancer at a young age, male breast cancer, triple-negative breast cancer, bilateral disease, or multiple primary cancers;
  • epithelial ovarian, fallopian tube, or primary peritoneal cancer;
  • pancreatic cancer or metastatic, high-risk, or selected localized prostate cancer;
  • colorectal or endometrial cancer with mismatch-repair deficiency, early onset, multiple primaries, polyposis, or a strong family history;
  • diffuse gastric cancer, multiple gastric cancers, or lobular breast cancer in a suggestive family;
  • kidney cancer at a young age, bilateral or multifocal tumors, unusual histology, or syndromic features;
  • medullary thyroid cancer, pheochromocytoma, paraganglioma, multiple endocrine tumors, or hyperparathyroidism in a suggestive pattern;
  • melanoma with pancreatic cancer or multiple affected relatives;
  • childhood or young-adult cancers associated with a predisposition syndrome;
  • a pathogenic variant suspected on tumor sequencing; or
  • a known pathogenic variant in a blood relative.

Professional guidelines may recommend testing broadly within a cancer type. For example, current breast-cancer guidance offers BRCA1 and BRCA2 testing to most patients diagnosed at age 65 or younger and to selected older patients based on personal history, ancestry, family history, or treatment relevance. Ovarian cancer and pancreatic cancer have broad germline-testing recommendations. Metastatic prostate cancer also commonly triggers germline testing.

Family history remains important even as criteria expand. A three-generation history should include the cancer site, age at diagnosis, both maternal and paternal relatives, multiple primary cancers, benign syndromic features, ancestry, and pathology when known. “Female cancers” or “stomach problems” are too vague; records can reveal ovarian versus uterine cancer or gastric cancer versus a benign ulcer.

Testing an affected relative first is usually most informative. If several relatives have cancer, choose someone with the youngest diagnosis, rarest tumor, multiple primaries, or strongest syndrome features when possible. Testing an unaffected person first can produce a negative result that does not explain the family pattern.

A person may qualify even without a large family history. Small families, adoption, early deaths, limited information, few relatives of the relevant sex, and preventive surgery can hide inherited risk. A de novo variant can also arise for the first time in a patient.

Testing is not only about estimating future risk. A current cancer diagnosis may make the result time sensitive because it can influence surgical planning, use of a PARP inhibitor, immunotherapy in a mismatch-repair syndrome, or eligibility for a clinical trial. The genetics referral should not be delayed until treatment is complete when a result could affect care now.

Choosing the right genes and laboratory

The panel should include genes with a reasonable connection to the personal or family history and enough evidence to support clinical action. ASCO guidance recommends considering the patient’s phenotype, cancer type, and the clinical utility of included genes rather than automatically choosing the broadest panel.

A focused panel may be preferable when:

  • the tumor and family history strongly indicate one syndrome group;
  • results are needed quickly for a treatment decision;
  • the patient wants to limit uncertain or unexpected findings;
  • insurance coverage is restricted; or
  • the laboratory’s focused assay offers better technical coverage.

A broader panel may be preferable when several syndromes overlap, the family diagnoses are uncertain, the tumor type is genetically heterogeneous, or previous single-gene testing was negative. For instance, hereditary breast cancer can involve BRCA1, BRCA2, PALB2, TP53, PTEN, CDH1, ATM, CHEK2, and other genes. A modern BRCA1 and BRCA2 test may be part of a panel rather than ordered alone.

Panel size affects the chance of a VUS. Every person has genetic variation, so examining more genes creates more opportunities to find rare changes whose meaning is unknown. This is not a laboratory failure, but it must be anticipated.

Before ordering, review:

  • all genes included and why each group is relevant;
  • whether the test includes deletion and duplication analysis;
  • coverage of difficult exons, promoters, or pseudogene regions;
  • the laboratory’s accreditation and variant-classification process;
  • whether RNA analysis is used to clarify splice variants;
  • whether mosaicism can be detected and at what level;
  • whether data are reanalyzed and how reclassification is communicated;
  • whether the patient can decline secondary or unrelated findings; and
  • out-of-pocket cost, insurance authorization, and financial assistance.

Blood is the most common specimen. Saliva and cheek swabs can work well but contain variable DNA and blood-cell contamination. A cultured skin fibroblast sample may be necessary after allogeneic bone marrow transplant, in active hematologic malignancy, or when clonal hematopoiesis makes a blood result uncertain.

A pathogenic variant found at a low allele fraction in blood can reflect mosaicism or clonal hematopoiesis rather than a fully germline change. This is especially relevant for genes such as TP53, ATM, CHEK2, and DNA-repair genes in older adults or people exposed to chemotherapy. Confirmation in non-blood tissue may be needed before making family-risk conclusions.

Turnaround commonly ranges from two to six weeks. Rapid testing may be available when surgery or systemic treatment depends on the result. The team should verify that the expedited panel still includes the necessary genes and variant types.

Understanding positive, negative, and VUS results

A hereditary panel can produce several result types, and each has a different level of certainty.

Pathogenic or likely pathogenic variant

A pathogenic variant has strong evidence that it disrupts gene function and causes or contributes to a hereditary cancer syndrome. A likely pathogenic variant has a greater than 90% probability of being disease-causing under commonly used classification standards. Both are generally managed as positive.

The clinical meaning depends on the gene. A BRCA1 pathogenic variant can raise breast and ovarian cancer risk and influence PARP-inhibitor treatment. An MSH6 variant causes a form of Lynch syndrome with a different risk profile from MLH1. A monoallelic MUTYH variant has different implications from biallelic variants. The gene name alone is not enough; inheritance pattern and variant state matter.

A positive result does not mean cancer is inevitable. Penetrance varies, and risk estimates are ranges based on groups. Age, sex, family history, lifestyle, reproductive factors, and competing health risks affect an individual plan.

Negative result

A true negative occurs when the family’s pathogenic variant is known and the tested person does not carry it. Their risk from that specific syndrome usually returns to the level expected from the rest of their history.

An uninformative negative occurs when no familial cause is known. It may mean no inherited syndrome is present, but it can also reflect a gene not tested, a variant outside assay coverage, limited scientific knowledge, or a family risk that is multifactorial. Screening may still be increased because of personal or family history.

A negative result after older testing deserves review. Early BRCA tests sometimes omitted large rearrangements or other genes now known to be important. Updated panel testing may be appropriate, but repeating a comprehensive modern test without a new reason is less likely to help.

Variant of uncertain significance

A VUS is a rare change with insufficient or conflicting evidence. It should not be used for risk-reducing mastectomy, hysterectomy, colectomy, organ screening, or targeted family testing. Care should follow the person’s actual history until the variant is reclassified.

Most VUS reclassifications move toward benign rather than pathogenic. Relatives should not be told that they “have the family mutation” based on a VUS. The genetic variant classification should be reviewed with a genetics professional when wording is unclear.

Unexpected or secondary finding

A broad panel may identify a pathogenic variant unrelated to the original referral. For example, a renal-cancer panel could reveal a breast-cancer gene, or a broad sequencing test might identify a medically actionable cardiovascular gene if secondary findings were requested. The consent process should explain what the laboratory reports and whether the patient can opt out.

Conflicting classifications can occur between laboratories. One may call a variant uncertain while another calls it likely pathogenic. Management should consider the evidence, the laboratory’s reasoning, expert databases, and whether confirmatory review is needed—not simply choose the more alarming label.

How results can change cancer care

A positive result can affect current treatment, risk of second cancers, and prevention for unaffected organs. The action must be gene specific.

Treatment and surgery

BRCA1, BRCA2, PALB2, and other homologous-recombination genes can influence PARP-inhibitor use in breast, ovarian, pancreatic, and prostate cancers. Mismatch-repair gene variants can explain microsatellite instability and support immune-checkpoint therapy in appropriate tumors. Germline RET variants affect medullary thyroid cancer management, while inherited kidney-cancer genes influence surgical timing and the need to preserve renal tissue.

A result can influence local surgery. A person with a high-risk breast gene may consider bilateral mastectomy rather than breast-conserving surgery, but survival benefit, age, tumor features, reconstruction, and preferences require careful discussion. A Lynch syndrome result can affect the extent of colorectal surgery and gynecologic risk-reduction planning. Testing should be completed early enough to inform these choices when possible.

Screening and prevention

Management may include earlier or more frequent imaging, endoscopy, dermatology examinations, laboratory testing, or preventive medication. Examples include breast MRI, colonoscopy at shortened intervals, pancreatic surveillance in selected high-risk carriers, renal MRI, or endocrine biochemical screening.

Risk-reducing surgery can lower cancer risk for some genes, but it is not automatically recommended for every pathogenic variant. Evidence is strong for removal of the fallopian tubes and ovaries at gene-specific ages in many BRCA1 or BRCA2 carriers. Evidence is less direct for some moderate-risk genes. Decisions should not be copied from a relative whose gene or medical circumstances differ.

A Lynch syndrome panel result illustrates why gene-specific advice matters: colon, endometrial, ovarian, urinary tract, and other risks differ among MLH1, MSH2, MSH6, PMS2, and EPCAM.

Limits of risk estimates

Published risks can change as studies include more people who were not selected from high-risk families. A variant found through population testing may have lower average penetrance than the same gene first described in families with many cancers. Family history can modify risk and may justify a more intensive plan within guideline ranges.

Moderate-risk genes often require a risk model that combines the variant with family history and other factors. A CHEK2 result, for example, should not be interpreted with the same ovarian-cancer recommendations as BRCA1. Clinical recommendations should name the gene and cite the current guideline rather than use a generic “positive panel” protocol.

Family testing, inheritance, and reproduction

Most hereditary cancer syndromes are autosomal dominant. A carrier’s children and full siblings often have a 50% chance of carrying the variant. Some conditions are autosomal recessive, such as biallelic MUTYH-associated polyposis, while others have X-linked or more complex inheritance.

Cascade testing begins with the exact pathogenic variant found in the family. Targeted testing is faster, less expensive, and easier to interpret than repeating a broad panel. A relative who tests negative for that variant is usually released from syndrome-specific screening, unless another branch of the family has an independent risk.

Testing children depends on whether medical care begins during childhood. Adult-onset BRCA-related testing is usually deferred until adulthood because childhood management does not change. APC, TP53, RET, VHL, FH, and several other syndromes can require childhood surveillance or preventive care, so earlier testing may be appropriate.

Families should receive a written result letter that includes the gene, exact variant, inheritance, associated risks, and how relatives can seek counseling. The tested person generally decides how and when to share the information because clinics may be limited in contacting relatives directly.

A relative’s negative result should be documented with the laboratory report. Verbal statements such as “my sister was negative” are often incomplete; she may have had only BRCA1/2 testing, a tumor test, or an uninformative panel before the family variant was found.

Reproductive options include natural conception, prenatal diagnosis, and in vitro fertilization with preimplantation genetic testing for a monogenic condition. Donor gametes, adoption, and choosing not to test a pregnancy are also options. These are personal decisions. Counseling should include test accuracy, timing, cost, and whether a rare combination of variants could cause a recessive childhood disorder.

Some genes create reproductive implications beyond adult cancer. Two partners with pathogenic variants in the same recessive DNA-repair gene could have a child with a severe condition. Examples include biallelic ATM, BRCA2, PALB2, and mismatch-repair variants in specific syndromes. Partner testing is considered according to the gene and family plans, not automatically for every result.

Preparation, privacy, and next steps

Before testing, gather pathology reports, ages and cancer sites for relatives, prior genetic reports, and ancestry information. Ask whether the result is needed before surgery or treatment. A genetic counselor can help choose a panel that is broad enough to answer the question without adding poorly supported genes.

Consent should address:

  • possible positive, negative, VUS, and unexpected results;
  • limits of the assay;
  • family implications;
  • reclassification and recontact policies;
  • sample storage and research use;
  • access to raw data, if offered;
  • insurance billing and financial assistance; and
  • legal protections and their limits.

In the United States, federal law limits use of genetic information in health insurance and employment but does not cover life, disability, or long-term-care insurance in the same way. Rules differ by country and state. People concerned about future policies may wish to discuss timing before testing with a qualified professional; they should not cancel medically important care based on general internet advice.

After results, ask:

  1. Is this result germline, tumor-only, or confirmed in both?
  2. What is the exact gene, variant, and classification?
  3. Which cancer risks are well established for this gene, and which are uncertain?
  4. Does the result change my current cancer treatment or surgery?
  5. What screening or preventive care should begin now, and who will order it?
  6. Which relatives should be tested, and at what ages?
  7. Should my partner be tested for reproductive reasons?
  8. How will I learn about future variant reclassification or guideline updates?

A positive result should produce a written management plan, referrals, and a family-testing strategy. A negative result should produce a documented residual-risk assessment rather than the vague statement that “nothing genetic was found.” A VUS should be clearly marked as nonactionable.

Keep the original report permanently. Laboratories may merge, clinics may close, and terminology may change. The exact variant allows future clinicians to verify the interpretation and order targeted testing for relatives.

Panel testing is most valuable when the result is matched to the right clinical question. A carefully selected test can guide treatment and prevention across a family; an overly broad or poorly explained test can create uncertainty without improving care.

References

Disclaimer

This article provides general education and cannot select a genetic panel or interpret an individual result. Cancer-risk estimates, treatment options, and screening recommendations depend on the exact gene, variant, personal history, and current guidelines. Do not use a variant of uncertain significance as the sole reason for surgery, medication, or predictive testing of relatives.

RELATED ARTICLESMORE FROM AUTHOR